{"DataElement":{"publicId":"3377215","version":"2","preferredName":"Liver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"Stage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for hepatocellular carcinoma.","longName":"3179900v1.0:3377197v1.1","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3179900","version":"1","preferredName":"Liver Cancer Group Stage","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"2834593v1.0:3377203v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2834593","version":"1","preferredName":"Hepatocellular Carcinoma","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","longName":"C3099","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62421A44-5466-782E-E040-BB89AD437669","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3377203","version":"1","preferredName":"Stage Grouping Stage","preferredDefinition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8A0D768-D501-B646-E040-BB89AD435C86","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-02-10","modifiedBy":"ONEDATA","dateModified":"2012-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F52449-32B9-E6AE-E040-BB89AD434DB8","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-03","modifiedBy":"TAYLORT","dateModified":"2018-12-19","changeDescription":"12/19/18 TT transferred ownership from NCIP to NCI Standards. Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3377197","version":"1.1","preferredName":"Liver Cancer American Joint Committee on Cancer Edition 7 Group Stage","preferredDefinition":"A finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system.  Intrahepatic bile duct cancers are no longer included in this classification.  The staging of liver cancer now includes only hepatocellular carcinoma. (from AJCC 7th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3377197v1.1","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"13","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage unknown","valueDescription":"Stage Unknown","ValueMeaning":{"publicId":"3357508","version":"1","preferredName":"Stage Unknown","longName":"3357508","preferredDefinition":"A finding indicating that the extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Unknown","conceptCode":"C92207","definition":"The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D76279-6263-2CA8-E040-BB89AD434A54","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C73D1D5A-D4BD-BF4E-E040-BB89AD431197","beginDate":"2012-02-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"ONEDATA","dateModified":"2012-08-14","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Hepatocellular Carcinoma","ValueMeaning":{"publicId":"3187468","version":"1","preferredName":"Stage I Hepatocellular Carcinoma","longName":"3187468","preferredDefinition":"Stage I includes: T1, N0, M0.  T1: Solitary tumor without vascular invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Hepatocellular Carcinoma AJCC v6 and v7","conceptCode":"C5758","definition":"Stage I includes: T1, N0, M0.  T1: Solitary tumor without vascular invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AD91834-F19E-6284-E040-BB89AD435481","latestVersionIndicator":"Yes","beginDate":"2011-01-27","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","id":"C73D1D5A-D57E-BF4E-E040-BB89AD431197","beginDate":"2011-01-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"ONEDATA","dateModified":"2012-08-14","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Hepatocellular Carcinoma","ValueMeaning":{"publicId":"3187470","version":"1","preferredName":"Stage II Hepatocellular Carcinoma","longName":"3187470","preferredDefinition":"Stage II includes: T2, N0, M0.  T2: Solitary tumor with vascular invasion or multiple tumors none more than 5 cm.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Hepatocellular Carcinoma AJCC v6 and v7","conceptCode":"C5759","definition":"Stage II includes: T2, N0, M0.  T2: Solitary tumor with vascular invasion or multiple tumors none more than 5 cm.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AD91834-F1C4-6284-E040-BB89AD435481","latestVersionIndicator":"Yes","beginDate":"2011-01-27","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","id":"C73D1D5A-D592-BF4E-E040-BB89AD431197","beginDate":"2011-01-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"ONEDATA","dateModified":"2012-08-14","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Hepatocellular Carcinoma","ValueMeaning":{"publicId":"3179931","version":"1","preferredName":"Stage IIIA Hepatocellular Carcinoma","longName":"3179931","preferredDefinition":"Stage IIIA includes: T3a, N0, M0.  T3a: Multiple tumors more than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Hepatocellular Carcinoma AJCC v7","conceptCode":"C5761","definition":"Stage IIIA includes: T3a, N0, M0.  T3a: Multiple tumors more than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F52449-3427-E6AE-E040-BB89AD434DB8","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","id":"C73D1D5A-D5A6-BF4E-E040-BB89AD431197","beginDate":"2011-01-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"ONEDATA","dateModified":"2012-08-14","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Hepatocellular Carcinoma","ValueMeaning":{"publicId":"3179929","version":"1","preferredName":"Stage IIIB Hepatocellular Carcinoma","longName":"3179929","preferredDefinition":"Stage IIIB includes: T3b, N0, M0. T3b: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Hepatocellular Carcinoma AJCC v7","conceptCode":"C5762","definition":"Stage IIIB includes: T3b, N0, M0. T3b: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F52449-3401-E6AE-E040-BB89AD434DB8","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","id":"C73D1D5A-D5BA-BF4E-E040-BB89AD431197","beginDate":"2011-01-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"ONEDATA","dateModified":"2012-08-14","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Stage IIIC Hepatocellular Carcinoma","ValueMeaning":{"publicId":"3179927","version":"1","preferredName":"Stage IIIC Hepatocellular Carcinoma","longName":"3179927","preferredDefinition":"Stage IIIC includes: T4, N0, M0.  T4: Tumors(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Hepatocellular Carcinoma AJCC v7","conceptCode":"C88044","definition":"Stage IIIC includes: T4, N0, M0.  T4: Tumors(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F52449-33DB-E6AE-E040-BB89AD434DB8","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","id":"C73D1D5A-D5CE-BF4E-E040-BB89AD431197","beginDate":"2011-01-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"ONEDATA","dateModified":"2012-08-14","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Hepatocellular Carcinoma","ValueMeaning":{"publicId":"3179923","version":"1","preferredName":"Stage IVA Hepatocellular Carcinoma","longName":"3179923","preferredDefinition":"Stage IVA includes: Any T, N1, M0.  N1: Regional lymph node metastasis. M0: No distant metastasis.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Hepatocellular Carcinoma AJCC v7","conceptCode":"C5764","definition":"Stage IVA includes: Any T, N1, M0.  N1: Regional lymph node metastasis. M0: No distant metastasis.  (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F52449-338F-E6AE-E040-BB89AD434DB8","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","id":"C73D1D5A-D5E2-BF4E-E040-BB89AD431197","beginDate":"2011-01-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"ONEDATA","dateModified":"2012-08-14","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Hepatocellular Carcinoma","ValueMeaning":{"publicId":"3179921","version":"1","preferredName":"Stage IVB Hepatocellular Carcinoma","longName":"3179921","preferredDefinition":"Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Hepatocellular Carcinoma AJCC v7","conceptCode":"C5765","definition":"Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F52449-3369-E6AE-E040-BB89AD434DB8","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","id":"C73D1D5A-D5F6-BF4E-E040-BB89AD431197","beginDate":"2011-01-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"ONEDATA","dateModified":"2012-08-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3377196","version":"1","preferredName":"Liver Cancer TNM Finding v7 American Joint Committee on Cancer Stage Grouping Stage","preferredDefinition":"A finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system.  Intrahepatic bile duct cancers are no longer included in this classification.  The staging of liver cancer now includes only hepatocellular carcinoma. (from AJCC 7th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C90149:C39315:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver Cancer TNM Finding v7","conceptCode":"C90149","definition":"A finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system.  Intrahepatic bile duct cancers are no longer included in this classification.  The staging of liver cancer now includes only hepatocellular carcinoma. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B89F81C7-F87C-3BD0-E040-BB89AD434D7C","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-02-10","modifiedBy":"ONEDATA","dateModified":"2012-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C73D1D5A-D4A6-BF4E-E040-BB89AD431197","latestVersionIndicator":"Yes","beginDate":"2012-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"COOPERM","dateModified":"2012-08-14","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12 Versioned to make the VD consistent with other Stage standard VDs - changed PV value. mc 8/14/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3434440","version":"1","longName":"Liver","context":"NCIP"},{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"10000291","version":"1","longName":"Liver","context":"NCI Standards"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000689","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCI Standards"}]}],"AlternateNames":[{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Disease Stage","type":"Preferred Question Text","description":"Disease Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"C73D1D5A-D604-BF4E-E040-BB89AD431197","latestVersionIndicator":"Yes","beginDate":"2012-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-08-14","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12 Versioned for changes in VD. mc 8/14/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}